What is the recommended management for osteoporosis after completing five years of alendronate therapy?

Management After 5 Years of Alendronate

After completing 5 years of alendronate therapy, reassess fracture risk immediately—patients who remain at high risk should continue treatment for up to 10 years total, while those at low-to-moderate risk should take a bisphosphonate holiday with monitoring every 2-4 years. 1, 2

Risk Stratification Framework

The decision to continue or discontinue alendronate hinges on current fracture risk assessment:

Continue Alendronate (Years 6-10) if patient has:

• T-score ≤ -2.5 at the hip 1, 3
• History of fragility fractures (especially vertebral) 1
• Age ≥ 80 years 4
• Multiple risk factors for fracture despite treatment 1
• Prior major osteoporotic fracture or fracture during therapy 5

Evidence basis: The FLEX trial demonstrated that women with hip T-scores ≤ -2.5 who continued alendronate for 10 years had 55% fewer clinical vertebral fractures compared to those who stopped at 5 years 6, 5. However, nonvertebral fracture rates were similar between groups 6.

Take a Bisphosphonate Holiday if patient has:

• T-score > -2.5 at the hip 2, 3
• No fractures during the 5-year treatment period 2
• Remained fracture-free and stable 2, 3
• Age < 80 years with moderate risk profile 4

Bisphosphonate Holiday Protocol

Duration: Up to 5 years without therapy 1

Monitoring schedule during holiday:

• Reassess fracture risk every 2-4 years 1
• Measure BMD at these intervals 2
• Consider bone turnover markers (CTX, P1NP) 2, 3

Resume treatment if:

• BMD declines beyond the least significant change (LSC) of the DXA machine 2, 3
• New fracture occurs 1, 3
• Bone turnover markers rise significantly 3
• Clinical circumstances change increasing fracture risk 1

Critical Considerations

Why holidays are possible with alendronate: Bisphosphonates accumulate in bone with prolonged residence time, providing residual anti-fracture effects after discontinuation 7. The FLEX trial showed bone turnover markers and BMD remained above pretreatment levels even 5 years after stopping 6.

The vertebral fracture caveat: While nonvertebral fractures showed no difference, clinical vertebral fractures were 55% lower in those continuing versus stopping alendronate (2.4% vs 5.3%) 6, 5. This is the primary reason high-risk patients should continue therapy.

Rare but serious risks with extended use: Atypical femoral fractures and osteonecrosis of the jaw increase with treatment duration beyond 5 years 3, 5. However, these rare events (affecting <1% of patients) are outweighed by vertebral fracture reduction in high-risk individuals 5.

Alternative Strategies for Very High-Risk Patients

If a patient at very high risk cannot tolerate continued bisphosphonates during years 6-10, consider:

• Switching to denosumab 60 mg subcutaneously every 6 months 1

  • Critical warning: Never stop denosumab without transitioning to another antiresorptive (including bisphosphonates) due to rebound bone loss and multiple vertebral fracture risk 1, 2, 1

• Anabolic therapy (teriparatide, abaloparatide) for up to 2 years in patients with severe/multiple vertebral fractures 1, 2

  • Must follow with antiresorptive therapy (bisphosphonate or denosumab) to maintain gains 1, 2, 1

Practical Algorithm

1. At 5-year mark: Obtain DXA scan of hip and spine
2. Calculate current fracture risk using FRAX or equivalent tool
3. Check hip T-score:
   • If ≤ -2.5 → Continue alendronate to 10 years
   • If > -2.5 AND no fractures → Holiday with monitoring
4. During holiday: DXA every 2-4 years, resume if BMD drops significantly or fracture occurs
5. After 10 years total treatment: Consider extended holiday with close monitoring, as risk-benefit beyond 10 years is unknown 3

The evidence strongly supports that most postmenopausal women can safely discontinue alendronate after 5 years without significantly increased fracture risk, except for clinical vertebral fractures in the highest-risk subset 6, 5.